AGN News 168.15 04/28/2014 04:55:05 Allergan Inc (AGN)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Allergan Inc (AGN) 168.15 $AGN

IBD 50: Valeant Taking The Buyout Route To Growth
at Investor's Business Daily - Fri Apr 25, 5:42PM CDT
Valeant Pharmaceuticals (VRX) is using buyouts to boost its business. The diversified Canadian drugmaker has made a boatload of buyouts, including a couple of big ones. In August, Valeant wrapped up its $8.7 billion acquisition of eye-care giant...

Wachtell Sees 'Threat' in Ackman's Allergan Bid
at The Street - Fri Apr 25, 3:48PM CDT
Activist investor critic Wachtell Lipton said hedge fund Pershing Square Capital Management's role in Valeant Pharmaceuticals $45 billion bid for Allergan was a new threat to Corporate America.

AbbVie Beats on Q1 Earnings, Humira Soars - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 3:45PM CDT
AbbVie (ABBV) surpassed expectations in the first quarter on the back of strong Humira sales.

Novartis Misses on Earnings & Revs in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 11:00AM CDT
Novartis (NVS) reported first quarter 2014 earnings per share of $1.21. Core earnings per share came in at $1.31, up 6% from the year-ago period but missed the Zacks Consensus Estimate of $1.33.

Prestige Brands Acquires Insight for $750M
at The Street - Fri Apr 25, 10:52AM CDT
Deal for feminine care product maker caps an active week for pharmaceutical mergers.

AstraZeneca Misses Earnings But Up on Takeover Rumors - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 9:30AM CDT
AstraZeneca's first-quarter 2014 core earnings of $1.17 per American Depositary Share missed the Zacks Consensus Estimate of $1.20.

Stockholder Rights Plan, Quarterly Results, Clinical Trial Results, Purchase Agreements, and New Contracts - Analyst Notes on Allergan, Gilead, Pfizer, Actavis and Express Scripts
PR Newswire - Fri Apr 25, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Allergan, Inc. (NYSE: AGN), Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), Actavis plc (NYSE: ACT) and Express Scripts Holding Company (NASDAQ: ESRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1586-100free.

Update on Glaxo/Theravance's COPD Drugs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 5:33PM CDT
Glaxo (GSK) and partner Theravance (THRX) announced the initiation of a phase III study on Relvar Ellipta.

Inside Valeant Pharmaceuticals' Bid for Allergan
Brendan Mathews, The Motley Fool - Motley Fool - Thu Apr 24, 5:30PM CDT
Earlier this week, Valeant Pharmaceutical made a public offer to buy rival Allergan . Let's review the major questions this huge potential deal raises, to see whether it's a smart move – and whether or not it'll actually happen. What is...

Valeant Eyes Allergan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 4:40PM CDT
Shares of Allergan (AGN) gained 15.2% after Valeant Pharmaceuticals International, Inc. (VRX) and Pershing Square Capital Management, L.P made a formal proposal to acquire the former.

Valeant And Pershing Square Investor Meeting Webcast Replay And Presentations Now Available
CNW Group - Thu Apr 24, 2:16PM CDT
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) and Pershing Square Capital Management L.P. ("Pershing Square" today announced that they have released the webcast replay and accompanying presentations from the April 22, 2014 investor meeting featuring Valeant Chairman and Chief Executive Officer, J. Michael Pearson and Pershing Square Chief Executive Officer, William A. Ackman, outlining Valeant's proposed acquisition of Allergan, Inc. (NYSE: AGN). The webcast and presentations can be accessed by visiting www.vpsevent.com/webcast.

Eli Lilly Q1 Earnings In-Line, Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 12:50PM CDT
Eli Lilly's (LLY) first quarter revenues were hurt by the genericization of two major products - Cymbalta and Evista.

Zimmer Bolts on Biomet for $13.4B
at The Street - Thu Apr 24, 10:47AM CDT
Sponsors Blackstone, TPG, KKR and Goldman forgo planned IPO in sale of orthopedic device maker.

Botox at the Center of Recent Healthcare M&A Flurry
at The Street - Thu Apr 24, 10:07AM CDT
How wrinkle reduction is at the crux of the recent M&A frenzy....

Jim Cramer's 'Mad Money' Recap: The Market's New Reality
at The Street - Wed Apr 23, 7:20PM CDT
Investors are focusing on the positive instead of the negative, Cramer says.

Encouraging Results from Pfizer's Xeljanz - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 5:20PM CDT
Pfizer Inc. (PFE) announced encouraging top-line results from two pivotal phase III studies from the OPT Program on Xeljanz.

Fitch Places Allergan's Ratings on Negative Watch
Business Wire - Wed Apr 23, 2:32PM CDT
Fitch Ratings has placed the ratings for Allergan Inc. (Allergan), including the 'A+' Issuer Default Rating (IDR), on Rating Watch Negative. The rating action stems from Valeant Pharmaceuticals International Inc.'s (Valeant) unsolicited offer to acquire Allergan for approximately $45.6 billion. The rating action applies to $2.1 billion of outstanding Allergan debt. A complete list of ratings is provided at the end of this release.

Can Allergan Find an Alternative To Valeant?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Wed Apr 23, 1:30PM CDT
No one will accuse Valeant CEO Mike Pearson of lacking boldness. He has laid out a strategy for turning Valeant into one of the largest pharmaceutical/med-tech companies in the world and has proven more than willing to turn to bold...

Stock Market News for April 23, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 9:06AM CDT
Benchmarks ended higher on Tuesday boosted by better-than-expected corporate results
Scroll down for more posts ▼

Top 10 Most Recent News Articles

AppLovin Faces Legal Heat: Investors on Edge Today

Updated Category News Views 43

AppLovin's Day of Reckoning: Investors Take Note Ever find yourself caught in a whirlwind of corporate promises that slide into disappointment? Well, buckle up, because that's exactly where AppLovin finds itself today. They've stirred up a storm with investors over some questionable hyperbole about their artificial intelligence tools and ad services. Missteps and Market...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 73

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading
Lululemon Faces Class Action over Alleged Missteps

Updated Category News Views 19

Trouble Brewing for Lululemon Y'ever get that gut feeling when something doesn't smell right? Well, Lululemon Athletica (NASDAQ: LULU) investors are probably feeling that now. A class action's kicking up dust over what some are saying was a downright bumpy ride. The brainiacs at Robbins LLP urge those who've lost bucks riding the LULU train to step forward ahead of the...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 223

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Sharon Stuart's Quest for Her Hidden Origins

Updated Category News Views 0

Delving Into Identity: A Personal Odyssey In a world where everyone seems to be searching for something, Sharon Stuart's quest is etched with the raw need to uncover her real origins. Abandoned as a newborn in the gritty streets of Oakland, she grew up grappling with looming questions about what made her who she is. Her journey is captured in her memoir, "Existing Without...

Continue Reading
Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 108

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
NaLA Pushes for Stronger Lifeline Fraud Measures

Updated Category News Views 14

Here's the thing about the Lifeline program: it's meant to be a lifeline, not a loophole for the crafty and unscrupulous. The National Lifeline Association (NaLA) is slamming the table, demanding that the Senate Commerce Committee put some real muscle into preventing fraud. Why the Urgency on Lifeline Fraud? NaLA’s got its sights on a more robust defensive line against...

Continue Reading
MoneyGram and Solflare Boost Crypto Cash-Out Options

Updated Category News Views 94

Crypto Meets Cash: A New Partnership in Money Movement Here's something to chew over your morning joe: MoneyGram's stepping up its game in the crypto world. They're pairing up with Solflare to let folks convert their USDC into hard cash across 170 countries and territories—no fees until New Year's Eve. It's like crypto's getting a passport to the physical world and not...

Continue Reading
ISC2 Launches AI Security Academy for Cyber Pros

Updated Category News Views 77

AI-Driven Threats Demand Expert Attention Every corner of the tech world has been blabbering about AI, but when it comes to cybersecurity, it's a whole different beast entirely. ISC2—a nonprofit that I like to think of as the cyber wizards’ guild—just threw a lifeline to cybersecurity folks who are swimming in the deep end of AI. With their shiny new AI Security...

Continue Reading
Lilly Endowment Boosts Military Families with $10M Grant

Updated Category News Views 20

A Game-Changer for Semper Fi & America's Fund Dive in, folks. What we've got here is a hefty chunk of change — $10 million to be precise — dropped into Semper Fi & America's Fund's lap by Lilly Endowment Inc. We're talking about a grant designed to shore up the long-term support system crafted for the brave souls in military families. It’s about time a significant...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting New Experiences Coming to Myrtle Beach in 2025

Updated Category News Views 1799

Discover What's New and Exciting in Myrtle Beach Fresh, unique adventures await at The Beach. As one of the Southeast's most beloved travel destinations, Myrtle Beach is gearing up for an exciting new year filled with unforgettable new and expanded experiences, alongside its iconic offerings that continue to draw visitors to its golden shores from across the nation. With...

Continue Reading
NXP Semiconductors Showcases Strong Energy and Growth Initiatives

Updated Category News Views 250

NXP Semiconductors Posts Impressive Q3 2025 Financial Results NXP Semiconductors N.V. (NASDAQ: NXPI) has announced its financial results for the third quarter, revealing a revenue of $3.17 billion. This performance exceeded market expectations and places NXP in a strong position amidst improving economic conditions. The company's president, Rafael Sotomayor, highlighted...

Continue Reading
Red Pine Exploration Secures Significant Funding Through Placement

Updated Category News Views 81

Red Pine Exploration Announces Major Funding Initiative Today, Red Pine Exploration Inc. (TSXV: RPX, OTCQB: RDEXF) has captured attention with its announcement of a significant C$7.0 million private placement. This deal, arranged by Haywood Securities Inc. and Research Capital Corporation, sets the stage for the company’s growth while bolstering its gold exploration...

Continue Reading
Ken Griffin Critiques Trump's Tariff Policies Impacting Economy

Updated Category News Views 172

Ken Griffin's Strong Critique of Tariff Policies Ken Griffin, known as the CEO of Citadel LLC, has emerged as a vocal critic of former President Donald Trump's tariff policy, labeling it as detrimental to the American economy. Griffin's stance marks a significant shift from his previous support for Trump, and he is urging for a reevaluation of the existing economic...

Continue Reading
Investigation Launched into Spyre Therapeutics by Pomerantz

Updated Category News Views 175

Pomerantz LLP Investigates Spyre Therapeutics, Inc. Pomerantz LLP is currently conducting an investigation on behalf of investors in Spyre Therapeutics, Inc. (NASDAQ: SYRE). This investigation seeks to uncover whether the company, along with its officials and directors, has engaged in fraudulent activities or other illicit business practices. Investors who believe they...

Continue Reading